Overview

* Adial Q3 net loss of $1.8 mln beats analyst expectations

* Company's R&D expenses decrease by 50% due to lower clinical activity

* Adial advances towards Phase 3 development of AD04 after successful FDA meeting

Outlook

* Adial is advancing to Phase 3 trials for AD04 following FDA guidance

* Company sees potential benefits from legislative support for broader trial endpoints

* Adial partners with Genomind for a companion diagnostic test for AD04

Result Drivers

* R&D EXPENSES DECREASE - Lower clinical activity led to a 50% decrease in R&D expenses, contributing to reduced net loss

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$1.80 -$2.12

Income mln mln (3

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Adial Pharmaceuticals Inc ( ADIL ) is $2.00, about 84.1% above its November 13 closing price of $0.32

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)